Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-05-21 EDT 5-day change 1st Jan Change
4,133 JPY -0.77% Intraday chart for Takeda Pharmaceutical Company Limited +0.76% +1.95%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment MT
Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification MT
FDA extends review of Ascendis Pharma's hormone disorder therapy RE
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute MT
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute MT
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care MT
Top Midday Gainers MT
AC Immune Enters Licensing Deal for Alzheimer's Disease Drug Candidate MT
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate MT
AC Immunity Shares Soar on Exclusive License Deal with Takeda DJ
Takeda Pharmaceutical's Attributable Profit Falls 55% in Fiscal 2024 MT
Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup DJ
Sector Update: Health Care Stocks Steady Pre-Bell Thursday MT
Transcript : Takeda Pharmaceutical Company Limited, 2024 Earnings Call, May 09, 2024
Takeda Pharmaceutical's Fiscal Q1 Core Earnings Decline, Revenue Increases; Fiscal 2024 Outlook Issued MT
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss -- Update DJ
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss DJ
Japan's Takeda Pharma says full-year profit slumps 56% RE
Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon CI
Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Full Year of 2024 CI
Takeda Pharmaceutical Company Limited Declares Dividend for the Year Ended March 31, 2024, Payable June 27, 2024; Provides Dividend Guidance for the Second Quarter-End and Year-End of Fiscal Year Ending March 31, 2025 CI
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion RE
EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug MT
Hutchmed notes CHMP's positive opinion for fruiquintinib approval AN
Chart Takeda Pharmaceutical Company Limited
More charts
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,133 JPY
Average target price
4,762 JPY
Spread / Average Target
+15.23%
Consensus
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. News Takeda Pharmaceutical Company Limited
  5. Takeda Pharmaceutical Receives FDA Approval to Expand Iclusig's Indication in Blood Cancer Sub-Type
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW